论文部分内容阅读
研究慢性心力衰竭患者血清赖氨酰氧化酶样蛋白2(lysyl oxidase like 2,LOXL2)水平变化情况,探讨LOXL2在心力衰竭诊断中的应用价值.入选心力衰竭住院患者74例,按纽约心功能分级标准分为心功能Ⅱ级组26例、心功能Ⅲ级组27例、心功能Ⅳ级组21例,并收集38例同期住院非心衰患者作为对照组.采集入选者的临床资料,入院后行心脏彩色超声检查,测定血浆NT-proBNP水平,采用酶联免疫法测定血清LOXL2浓度.患者血清LOXL2水平在心功能Ⅳ级组(992.1±404.5) pg/mL显著高于心功能Ⅲ,Ⅱ级组[分别为(637.1±125.8)和(467.5±88.7) pg/mL,均P＜0.01]及对照组[(314.2±143.5) pg/mL,P＜0.01],与对照组相比,各组心衰患者LOXL2水平均显著升高(均P＜0.05).LOXL2浓度与左室舒张末期内径(LVEDd)呈正相关(R2=0.25,P＜0.01)、而与心功能分级(R2=-0.26,P＜0.01)呈负相关.血清LOXI2诊断心力衰竭的ROC曲线下面积(AUC)为0.699,95％可信区间为(0.644 ～0.894,P＜0.001).心力衰竭患者血清LOXL2水平明显升高,并且升高水平与心力衰竭程度显著相关.LOXL2或可作为NT-proBNP和超声心动图外的补充手段,对心力衰竭的诊断与鉴别有一定意义.“,”To investigate the roles of serum lysyl oxidase like 2 (LOXL2) level in patients with heart failure (HF),this study included 74 hospitalized patients with HF.Of whom,26 were classified as NYHA functional class Ⅱ patients,27 were NYHA Ⅲ,and 21 were NYHA Ⅳ patients.Thirty-eight control subjects without HF were recruited as control group.All subjects accepted UCG examination at admission and the serum aminoterminal B-type natriuretic peptide (NT-proBNP) were measured.LOXL2 levels were determined by enzyme-linked immunosorbent assays.The levels of serum LOXL2 were significantly higher in patients with NYHA functional class Ⅳ (992.1 ±404.5) pg/mL than in patients with NYHA Ⅲ (637.1 ± 125.8) pg/mL,P ＜0.01 and patients with class Ⅱ (467.5 ± 88.7) pg/mL,P ＜ 0.01.Furthermore,all group of HF patients had higher levels of LOXL2 than those in controls group (all P ＜ 0.05).Correlation analysis further demonstrated that the serum LOXL2 levels were correlated with the left ventricular end-diastolic diameter (LVEDd) (R2 =0.25,P ＜ 0.01) and left ventricular ejection fraction (LVEF) (R2 =-0.26,P ＜ 0.01).Received characteristic curves (ROC) for diagnosis of heart failure demonstrated an AUC of 0.699 (0.674 ～ 0.894,P ＜ 0.001) for LOXL2 (P ＜0.01).In addition,the ROC of NT-proBNP for diagnosis of heart failure had an AUC of 0.863 (0.781 ～0.944,P ＜0.001).The level of serum LOXL2 is significantly increased in patients with HF.It may be a new biomarker of HF and can provide additive information to NT-proBNP levels in the diagnosis of HF.